Osteoporosis Management Note (DXA Review & Antiresorptive Therapy)

Visit Date: [Date]

Patient Name: [Full name]

Age/Sex: [Age] / [Sex]

Encounter Type: [new / established]; [telehealth / in-person]

Referring Provider / PCP: [Name and role]

Chief Concern

[Patient-centered reason for visit and goal] (Use concise language; include a brief patient quote only if it clarifies the visit goal.)

Visit Purpose

[One to two sentences identifying this as an osteoporosis co-management visit focused on DXA review and pharmacologic fracture-risk reduction, with relevant context such as menopausal status or comorbidities affecting bone management] (Only include comorbidities if explicitly relevant to bone health decisions.)

Osteoporosis History

[Brief narrative summary of osteoporosis timeline: how diagnosis was established, prior therapies with approximate dates and duration, adherence, response, and any adverse effects] (Keep concise. Do not infer details not documented.)

• Fracture History: [Fragility fracture sites, dates, mechanism and trauma level; vertebral fracture suspicion and imaging status] (Document low- vs high-trauma context. Include VFA/spine imaging status if mentioned.)
• Falls Risk: [Falls in past 12 months; gait/balance issues; vision problems; sedating medications; orthostasis] (Include only elements discussed.)
• Major Clinical Risk Factors: [Parent hip fracture; tobacco use; alcohol pattern; glucocorticoid exposure with dose, duration, current/past; inflammatory disease; secondary osteoporosis conditions] (Specify doses and durations when used to justify treatment.)
• Bone-Relevant Medications and Supplements: [Current and prior glucocorticoids, aromatase inhibitors, androgen deprivation therapy, anticonvulsants, PPIs; current calcium and vitamin D intake with approximate doses]
• Secondary Osteoporosis Screen: [CKD stage; nephrolithiasis; malabsorption or bariatric surgery; hyperparathyroidism; thyroid disease; hypogonadism or premature menopause; hematologic malignancy red flags; pending work-up] (Document positives, pertinent negatives, and pending tests.)
• Dental Status: [Last dental visit; planned extractions or implants; poor dentition; active oral infection] (Required for potent antiresorptives. If not addressed but needed for therapy, document as "Unknown / Not available" with plan to obtain.)
• Patient Preferences and Access: [Route preference: oral / IV / subcutaneous; ability to adhere to dosing schedule; infusion center access; cost or coverage considerations] (Capture barriers that influence agent selection.)

Records Reviewed

• [DXA report(s) with date(s), facility, and whether prior studies are from same device for comparability]
• [Relevant laboratory results with dates]
• [Spine or fracture imaging reports with dates]
• [Outside clinician notes or summaries with dates]

DXA Review and Interpretation

(Keep objective report details separate from clinical interpretation.)

Study Details: [DXA date; facility; device if known; indication; sites measured; technical quality and limitations such as degenerative changes or vertebrae excluded with reasons; comparability to prior studies] (State whether same machine/facility and if LSC is available.)

• Results by Site: (List each measured site on separate lines)
  • [Site]: BMD [value with units]; T-score [value]; Z-score [value if relevant]; [Percent change from prior if comparable] (Note if change exceeds LSC.)
  • (Repeat for each site measured)

Diagnostic Classification: [normal / low bone mass (osteopenia) / osteoporosis] — [Site driving classification; note if diagnosis is fracture-based or risk-based rather than BMD alone]

Fracture Risk Estimation: [FRAX major osteoporotic fracture %]; [FRAX hip fracture %]; Femoral neck BMD included: [yes / no] — [How risk estimate informed management] (Include only if a validated risk tool was used.)

Interpretation Summary: [Synthesis highlighting lowest clinically relevant T-score site; potential overestimation at lumbar spine if degenerative changes present; whether vertebral imaging is indicated; overall fracture risk category: low / moderate / high / very high]

If DXA Not Available: Status: [Not yet performed / Outside records pending / Other reason]. Provisional risk assessment: [Based on known fractures and clinical risk factors]. Plan: [Plan to obtain DXA report or schedule testing]. (Omit this section if DXA was reviewed above.)

Objective

• Vitals: Height [value]; Weight [value]; [Historical height and calculated height loss if available]
• Focused Exam: [Gait and balance; posture and kyphosis; spine tenderness if vertebral fracture suspected] (Omit if not performed.)
• Pertinent Labs: [Calcium with date]; [Creatinine and eGFR with date]; [25-OH vitamin D with date]; [Secondary-cause labs with dates and values if they inform therapy selection or safety]

Assessment

1. Osteoporosis or low bone mass with elevated fracture risk: [Basis: BMD category, fracture history, and/or risk thresholds]; Risk category: [high / very high] — [Features driving classification such as recent fracture, multiple fractures, very low T-score]
2. Secondary osteoporosis evaluation status: [Ruled out / Pending evaluation / Suspected] — [Brief rationale]
3. Vitamin D and calcium status: [Adequate / Insufficient / Deficient] — [Brief details]
4. Falls risk: [Present / Absent] — [Contributing factors if present] (Include if relevant to management.)
5. Therapy status: [Treatment-naïve / On therapy with agent name / Considering switch / Drug holiday candidate / Post-discontinuation planning]

Plan

Osteoporosis — Pharmacologic Therapy

• Indication and goals: [Why treatment is indicated now: fracture history, T-score threshold, FRAX threshold, rapid bone loss]; [Therapeutic goals]
• Agent selection: [Chosen agent: oral bisphosphonate / IV bisphosphonate / denosumab] — [Rationale addressing contraindications, prior intolerance, adherence feasibility, renal function, patient preference, access]
• Pre-treatment safety documentation:
  • Renal function: [eGFR or CrCl with date] — Suitable for planned agent: [yes / no] (For zoledronic acid, confirm CrCl >35 mL/min.)
  • Calcium and vitamin D status: [Values and adequacy]; [Hypocalcemia risk factors if any]
  • Dental status: [Up to date / Issues identified / Planned extractions or implants with timing] (If not addressed, document as "Unknown / Not available" with plan to obtain before initiating potent antiresorptive.)
• Administration details: [Dose]; [Schedule]; [Start or next due date]; [Site of administration]; [Required pre-dose labs and timing] (For denosumab, include missed-dose plan. For zoledronic acid, reaffirm creatinine clearance threshold.)
• Adverse effect counseling: [Common effects and mitigation discussed]; [Rare serious risks including ONJ and atypical femoral fracture reviewed]; Return precautions: [jaw pain or nonhealing oral lesions; thigh or groin pain; hypocalcemia symptoms]
• Duration and reassessment: [Timeframe for reassessing fracture risk and therapy need] (For bisphosphonates, note criteria and monitoring plan for potential drug holiday. For denosumab, document that therapy must not be stopped or delayed without a transition plan to another antiresorptive to prevent rebound bone loss; state intended transition strategy.)

Secondary Osteoporosis Evaluation

• [Labs ordered now with rationale] — [Who will review results and patient notification plan]
• [Referral triggers or current referrals: endocrinology, nephrology, gastroenterology as appropriate]

Calcium, Vitamin D, and Lifestyle

• Calcium plan: [Estimated dietary intake]; [Supplement dose and form to reach daily target]; [Constipation or nephrolithiasis considerations if relevant]
• Vitamin D plan: [Most recent level]; [Supplement dose]; [Recheck timing]; [Sufficiency target]
• Exercise and fall prevention: [Weight-bearing and resistance guidance]; [Balance training]; [PT referral if indicated]; [Home safety or vision review]
• Smoking and alcohol: [Counseling provided / Not applicable]

Monitoring and Follow-up

• DXA monitoring: [Timing for repeat DXA with rationale] (Prefer same facility and device for comparability.)
• Lab monitoring: [Calcium and creatinine monitoring cadence] (For denosumab in CKD, document enhanced calcium monitoring plan.)
• Next contact: [Follow-up interval]; Triggers for earlier review: [new fracture, intolerance, dental surgery scheduled, missed injection]

Orders

• [DXA order]
• [Laboratory orders]
• [Infusion or injection orders]
• [Referrals: dentistry, PT, specialty consultation]

(Do not infer fracture history, glucocorticoid exposure, menopausal status, renal function, or dental risk if not explicitly stated. If a risk factor is used to justify treatment, document the supporting detail. Core safety items for antiresorptive therapy—renal function, calcium and vitamin D status, dental status, and monitoring plan—must be documented; if not addressed, record "Unknown / Not available" with a plan to obtain. Keep DXA objective details separate from clinical interpretation. List Assessment problems in decreasing order of clinical severity. When documenting denosumab therapy, always include a statement about the transition plan if therapy were to be discontinued.)